Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
doxifluridine + tamoxifen
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy consisting of doxifluridine (5'-DFUR), an oral 5-FU derivative and prodrug of 5-fluorouracil, and tamoxifen (TAM), a selective estrogen receptor modulator. This combination is used primarily for the treatment of advanced or recurrent breast cancer, showing particular efficacy for metastatic lesions in soft tissue and the lung. Doxifluridine works as an antimetabolite after conversion to 5-FU, while tamoxifen competitively inhibits estrogen binding to its receptor, reducing tumor growth factors and inducing apoptosis in estrogen receptor positive cells.
- Other names
- 5'-DFUR + TAM
02
Targets
ER (Estrogen receptor)TS (Thymidylate synthase)
Beyond the preview
Go deeper on doxifluridine + tamoxifen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on doxifluridine + tamoxifen.